Trials / Completed
CompletedNCT05654298
Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin
Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The involvement of calcitonin gene-related peptide (CGRP) in the cinnamaldehyde-induced dermal blood flow increase and in the mechanism of action of triptans will be investigated. The capsaicin-induced dermal blood flow will be incorporated as a positive control; histamine skin pricks as a negative control. Changes in dermal blood flow will be measured with laser speckle contrast imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sumatriptan | Sumatriptan 100 mg |
| DRUG | Ubrogepant | Ubrogepant 100 mg |
Timeline
- Start date
- 2022-03-15
- Primary completion
- 2023-03-15
- Completion
- 2023-03-15
- First posted
- 2022-12-16
- Last updated
- 2023-03-28
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05654298. Inclusion in this directory is not an endorsement.